Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 13/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.37 |
| ▸ | AOC2 | O75106 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.35 |
| ▸ | USP2 | O75604 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25959053 | 0.92 | PIK3CD (0.38) | CYP2D6SMN1; SMN2PIK3CDAOC2USP2 | |
| SCHEMBL3422977 | 0.78 | PIK3CD (0.47) | CYP2D6SMN1; SMN2PIK3CDCYP3A4USP2 | |
| SCHEMBL22156260 | 0.76 | CHRM2 (0.38) | AOC2 | |
| SCHEMBL12758823 | 0.76 | OPRM1 (0.34) | CYP2D6SMN1; SMN2AOC2 | |
| SCHEMBL12832224 | 0.74 | CHRM2 (0.35) | CYP2D6AOC2 | |
| SCHEMBL12758825 | 0.74 | SMN1; SMN2 (0.36) | CYP2D6SMN1; SMN2AOC2 | |
| SCHEMBL24338550 | 0.74 | GRIN2B (0.44) | CYP2D6CYP3A4USP2CYP1A2TSHR | |
| SCHEMBL25664906 | 0.73 | PIK3CD (0.46) | CYP2D6SMN1; SMN2PIK3CDUSP2CYP1A2 | |
| SCHEMBL13431755 | 0.73 | PRMT1 (0.37) | AOC2ALDH1A1 | |
| SCHEMBL14684737 | 0.73 | AOC2 (0.34) | AOC2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | KRAS, NRAS, HRAS | CYP2D6 2362/4885SMN1; SMN2 3861/4885PIK3CD 180/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | CYP2D6 4714/4885SMN1; SMN2 1139/4885PIK3CD 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.